Is Sermorelin Legal in Ohio?

Print or save as PDF

Key numbers

  • 0.5 mgStrength of the original Geref vials, approved for idiopathic growth hormone deficiency in children with growth failureSource: federalregister.gov, as cited Nov 7, 2026
  • 30 micrograms per kgDose used in a historical pediatric growth hormone study; not a recommended doseSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
  • 14 daysLength of a historical study of 0.5 mg or 1 mg doses in older men; not a recommended doseSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026

See the public record for Sermorelin

  • Federal status / No FDA-approved sermorelin product; Geref's approvals ended June 18, 2009 [1]
  • How it is sold now / Compounded only; compounded drugs are not FDA-approved [2]
  • Approved uses (historic) / Test of pituitary growth hormone release; pediatric growth hormone deficiency [1]
  • Adult anti-aging, weight loss, athletics / Never approved for these uses [1]
  • FDA safety-risk list / Sermorelin does not appear on it (page dated 04/22/2026) [3]
  • Outsourcing-facility bulk list / Category 1, under evaluation (list updated March 21, 2025) [4]
  • Sport / Prohibited at all times by WADA, code S2.2.4 [5]
  • Ohio / The Ohio Board of Pharmacy enforces state pharmacy and drug-distribution law; no Ohio rule on sermorelin is cited here [6]

Start With the Federal Record

Sermorelin acetate reached the US market as Geref under two approvals. NDA 019863 covered a 0.05 mg/ampule product approved December 28, 1990 for evaluating the pituitary's ability to secrete growth hormone; NDA 020443 covered 0.5 mg and 1 mg vials approved September 26, 1997 for treating idiopathic growth hormone deficiency in children with growth failure [1].

The manufacturer discontinued both products in 2008 and asked FDA to withdraw the applications, and approval ended effective June 18, 2009 [1]. Those two uses were the only ones ever approved: Geref was not approved for adults, anti-aging, weight loss or athletic performance [1].

The exit was not a safety action. In March 2013 FDA determined that Geref was not withdrawn from sale for reasons of safety or effectiveness [1][7]. With no approved product left, sermorelin sold in the US today is compounded, and compounded drugs are not FDA-approved: FDA does not review their safety, effectiveness or quality before they are marketed [2].

Where Sermorelin Sits on the FDA Compounding Lists

The federal lists that shape peptide compounding each treat sermorelin differently.

  • FDA's list of bulk substances that may present significant safety risks (category 2), content dated 04/22/2026, does not include sermorelin [3].
  • FDA's list of nominated bulk substances for outsourcing facilities, updated March 21, 2025, places sermorelin acetate in category 1, under evaluation, with the list's symbol for substances that are components of FDA-approved drugs [4].
  • FDA's list for state-licensed pharmacies and physicians, updated May 14, 2026, does not place sermorelin in any category [8], and sermorelin is not one of the six peptides in HHS's October 2026 draft enforcement-discretion policy [9].

Ohio

The Ohio Board of Pharmacy describes itself as the single state agency responsible for administering and enforcing the state's pharmacy laws and the legal distribution of drugs [6]. Its general description does not mention sermorelin or peptides. The firm part of the picture is federal: there is no approved sermorelin product, and what is available is compounded [2].

Questions worth asking

Choose the questions you want to keep

Prescription Status Does Not Cover Sport

A separate rule applies to competition. WADA's 2026 Prohibited List names sermorelin in S2.2.4, growth hormone releasing factors, and prohibits it at all times, in and out of competition; S2 substances are non-Specified Substances [5]. The 2027 List, in force January 1, 2027, carries the same entry [10].

What the Drug Is, and What Doses Were Studied

Sermorelin is a 29-amino-acid analogue of growth hormone-releasing hormone, not growth hormone itself; it acts on the pituitary to prompt release of the body's own growth hormone [11].

With no approved product there is no current approved dose. The historical studies used 30 micrograms per kg once daily subcutaneously at bedtime in the pediatric growth hormone deficiency program, and 0.5 mg or 1 mg subcutaneously twice daily for 14 days in a study of older men [12][13]. Neither figure is a recommended dose.

Is sermorelin legal in Ohio?
No sermorelin product is FDA-approved today, Geref's approvals were withdrawn in 2009, and what is sold now is compounded [1][2]. This page cites no Ohio rule that names sermorelin.
Was sermorelin ever FDA-approved?
Yes, as Geref, under NDA 019863 for a diagnostic test of pituitary growth hormone release and NDA 020443 for pediatric growth hormone deficiency. The maker discontinued both in 2008 and FDA withdrew the approvals effective June 18, 2009 [1].
Why did Geref leave the market?
The manufacturer discontinued it and asked FDA to withdraw the applications. In March 2013 FDA determined that Geref was not withdrawn from sale for reasons of safety or effectiveness [1][7].
Is compounded sermorelin FDA-approved?
No. Compounded drugs are not FDA-approved, and FDA does not review their safety, effectiveness or quality before they are marketed [2].
Where does sermorelin appear on the FDA compounding lists?
It is absent from FDA's list of bulk substances that may present significant safety risks, listed as category 1 under evaluation on the outsourcing-facility list, and absent from the list for state-licensed pharmacies and physicians [3][4][8].
Does WADA prohibit sermorelin?
Yes. The 2026 and 2027 Prohibited Lists name sermorelin in S2.2.4 and prohibit it at all times, in and out of competition [5][10].
Show all 13 referencesHide references
  1. Federal Register :: Request Access.
  2. Official web page.
  3. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
  4. U.S. Food and Drug Administration.
  5. World Anti-Doping Agency.
  6. Ohio Board of Pharmacy.
  7. U.S. Food and Drug Administration.
  8. U.S. Food and Drug Administration.
  9. Official web page.
  10. World Anti-Doping Agency.
  11. Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999;12(2):139-57.
  12. Thorner M, Rochiccioli P, Colle M, Lanes R, Grunt J, Galazka A, et al. Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group. J Clin Endocrinol Metab. 1996;81(3):1189-96.
  13. Corpas E, Harman SM, Piñeyro MA, Roberson R, Blackman MR. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. J Clin Endocrinol Metab. 1992;75(2):530-5.
Is sermorelin legal in Ohio: evidence summary chart
Image: HealthRX.com. Full is sermorelin legal in Ohio guide and sources at healthrx.com/peptide-legal-sermorelin.